BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9672171)

  • 1. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.
    Duclos-Vallée JC; Nishioka M; Hosomi N; Arima K; Leclercq A; Bach JF; Yamamoto AM
    J Hepatol; 1998 Jun; 28(6):965-70. PubMed ID: 9672171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment.
    Dalekos GN; Wedemeyer H; Obermayer-Straub P; Kayser A; Barut A; Frank H; Manns MP
    J Hepatol; 1999 Mar; 30(3):366-75. PubMed ID: 10190716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.
    Ma Y; Peakman M; Lobo-Yeo A; Wen L; Lenzi M; Gäken J; Farzaneh F; Mieli-Vergani G; Bianchi FB; Vergani D
    Clin Exp Immunol; 1994 Jul; 97(1):94-9. PubMed ID: 8033426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.
    Yamamoto AM; Johanet C; Duclos-Vallee JC; Bustarret FA; Alvarez F; Homberg JC; Bach JF
    Clin Exp Immunol; 1997 Jun; 108(3):396-400. PubMed ID: 9182882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
    Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
    J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection.
    Ma Y; Gregorio G; Gäken J; Muratori L; Bianchi FB; Mieli-Vergani G; Vergani D
    J Hepatol; 1997 Jun; 26(6):1396-402. PubMed ID: 9210629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.
    Sugimura T; Obermayer-Straub P; Kayser A; Braun S; Loges S; Alex B; Lüttig B; Johnson EF; Manns MP; Strassburg CP
    Autoimmunity; 2002 Dec; 35(8):501-13. PubMed ID: 12765476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sera of children with hepatitis C infection and anti-liver-kidney microsome-1 antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera.
    Herzog D; Yamamoto AM; Jara P; Maggiore G; Sarles J; Alvarez F
    J Pediatr Gastroenterol Nutr; 1999 Nov; 29(5):551-5. PubMed ID: 10554122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.
    Miyakawa H; Kikazawa E; Abe K; Kikuchi K; Fujikawa H; Matsushita M; Kawaguchi N; Morizane T; Ohya K; Kako M
    Autoimmunity; 1999; 30(2):107-14. PubMed ID: 10435724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.
    Monti V; Aghemo A; Rumi MG; Donato MF; Del Ninno E; Colombo M
    Antivir Ther; 2005; 10(6):715-20. PubMed ID: 16218170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
    Klein R; Zanger UM; Berg T; Hopf U; Berg PA
    Clin Exp Immunol; 1999 Nov; 118(2):290-7. PubMed ID: 10540193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
    Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
    Wu CH; Xu XY; Tian GS; Yu YY
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
    Miyakawa H; Kitazawa E; Kikuchi K; Fujikawa H; Kawaguchi N; Abe K; Matsushita M; Matsushima H; Igarashi T; Hankins RW; Kako M
    Autoimmunity; 2000; 33(1):23-32. PubMed ID: 11204250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in antigenic sites, recognized by anti-liver-kidney microsome-1 (LKM-1) autoantibody, between HCV-positive and HCV-negative sera in Japanese patients.
    Miyakawa H; Matsushima H; Narita Y; Hankins RW; Kitazawa E; Fujikawa H; Kikuchi K; Matsushita M; Abe K; Kawaguchi N; Morizane T; Kako M
    J Gastroenterol; 1998 Aug; 33(4):529-35. PubMed ID: 9719237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA.
    Seelig R; Renz M; Bünger G; Schröter H; Seelig HP
    Clin Exp Immunol; 1993 Jun; 92(3):373-80. PubMed ID: 8390333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.
    Muratori L; Lenzi M; Ma Y; Cataleta M; Mieli-Vergani G; Vergani D; Bianchi FB
    Gut; 1995 Sep; 37(3):406-12. PubMed ID: 7590439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6.
    Komurasaki R; Imaoka S; Tada N; Okada K; Nishiguchi S; Funae Y
    Drug Metab Pharmacokinet; 2010; 25(1):84-92. PubMed ID: 20208391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.
    Betterle C; Fabris P; Zanchetta R; Pedini B; Tositti G; Bosi E; de Lalla F
    Diabetes Care; 2000 Aug; 23(8):1177-81. PubMed ID: 10937518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.